Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 44.30
- Piotroski Score 2.00
- Grade Buy
- Symbol (AVBP)
- Company ArriVent BioPharma, Inc. Common Stock
- Price $27.11
- Changes Percentage (-0.37%)
- Change -$0.1
- Day Low $26.49
- Day High $27.61
- Year High $36.37
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2024
- Fiscal Year End N/A
- Average Stock Price Target $36.00
- High Stock Price Target $36.00
- Low Stock Price Target $35.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-69,333,000
Income Statement
Quarterly
Annual
Latest News of AVBP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ArriVent BioPharma, Inc. (NASDAQ:AVBP) institutional investors have had a good week as stock gains 19%
ArriVent BioPharma, Inc. ownership breakdown reveals institutions with a 43% stake. Hedge funds own 5.8%, with top 8 shareholders holding over half. Insider ownership is at US$10....
By Yahoo! Finance | 3 months ago
